Recently, the angiotensin receptor blocker-neprilysin inhibitor sacubitril/valsartan has been introduced in clinical practice as treatment for HF showing its superiority to ACE inhibition alone in reducing the risks of death and hospitalization.[5–9] Indeed, sacubitril/valsartan influences the 2 HF pathophysiological mechanisms. Here, MME is linked to hydrops fetalis.